Search
Filter Results
Displaying 411–420 of 543 for “Retinitis pigmentosa”
-
Mar 25, 2024
Foundation NewsCollaboration will add a new multi-gene cohort of patients living with inherited retinal diseases. Data insights from the new study cohort will inform the future clinical trial design for BlueRock’s pipeline of cell therapies for treating blindness.
-
Jan 6, 2023
The Retinal Degeneration Fund invests in a $78M Series B for Perceive Biotherapeutics
In the PressThe investment supports the clinical development of two novel programs, both with the aim of being protective against vision loss.
-
May 10, 2022
Foundation NewsThe Foundation Fighting Blindness, the world’s leading organization committed to finding treatments and cures for retinal degenerative diseases, will host an online continuing medical education (CME and COPE) course on inherited retinal disease gene therapies on Thursday, June 9, 2022, at 7:00 p.m. EDT.
-
VISIONS 2022, the national conference of the Foundation Fighting Blindness, is a one-of-a-kind event in which individuals who are visually impaired, and their families, have the opportunity to hear about exciting advancements in blindness research.
-
Jan 29, 2021
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board
In the PressDevelopment of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board
-
-
Feb 6, 2020
Foundation NewsMy Retina Tracker Program is the highest volume IRD genetic testing program in the U.S.
-
Nov 27, 2019
Foundation NewsKnown as Pro-EYS, the study will help researchers design clinical trials for potential therapies
-
Oct 2, 2019
Foundation NewsThe program will offer patients with inherited retinal disease no-cost genetic testing and genetic counseling in the United States. Look for updated information on how to participate to be posted in mid-October, with program registration starting shortly thereafter.
-
Jun 18, 2018
Foundation NewsThree-day conference in San Diego will feature retinal science’s leading researchers and clinicians, and focus on the year’s top science and emerging treatments